We intend to demonstrate that GLP-1 analogues could be used as new tools for the treatment of these metabolic and adipose tissue disorders, reducing fat mass and insulin resistance, decreasing insulin requirements, and improving A1c. This evidence concerns the gene GLP1R and Insulin resistance.